[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse KMT2B

Summary
SymbolKMT2B
Namelysine (K)-specific methyltransferase 2B
Aliases KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF05965 F/Y rich C-terminus
PF05964 F/Y-rich N-terminus
PF00628 PHD-finger
PF00856 SET domain
PF02008 CXXC zinc finger domain
Function

Histone methyltransferase. Methylates 'Lys-4' of histone H3. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. Plays a central role in beta-globin locus transcription regulation by being recruited by NFE2. Plays an important role in controlling bulk H3K4me during oocyte growth and preimplantation development. Required during the transcriptionally active period of oocyte growth for the establishment and/or maintenance of bulk H3K4 trimethylation (H3K4me3), global transcriptional silencing that preceeds resumption of meiosis, oocyte survival and normal zygotic genome activation.

> Gene Ontology
 
Biological Process GO:0001541 ovarian follicle development
GO:0006338 chromatin remodeling
GO:0006479 protein methylation
GO:0007281 germ cell development
GO:0007292 female gamete generation
GO:0007548 sex differentiation
GO:0007611 learning or memory
GO:0007613 memory
GO:0008213 protein alkylation
GO:0008406 gonad development
GO:0008585 female gonad development
GO:0009994 oocyte differentiation
GO:0016458 gene silencing
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0018022 peptidyl-lysine methylation
GO:0018023 peptidyl-lysine trimethylation
GO:0018205 peptidyl-lysine modification
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0022602 ovulation cycle process
GO:0030728 ovulation
GO:0031056 regulation of histone modification
GO:0031060 regulation of histone methylation
GO:0032259 methylation
GO:0034968 histone lysine methylation
GO:0040029 regulation of gene expression, epigenetic
GO:0042698 ovulation cycle
GO:0043414 macromolecule methylation
GO:0044708 single-organism behavior
GO:0045137 development of primary sexual characteristics
GO:0045815 positive regulation of gene expression, epigenetic
GO:0046545 development of primary female sexual characteristics
GO:0046660 female sex differentiation
GO:0048096 chromatin-mediated maintenance of transcription
GO:0048477 oogenesis
GO:0048511 rhythmic process
GO:0048608 reproductive structure development
GO:0050890 cognition
GO:0051568 histone H3-K4 methylation
GO:0051569 regulation of histone H3-K4 methylation
GO:0061458 reproductive system development
GO:0080182 histone H3-K4 trimethylation
GO:1902275 regulation of chromatin organization
Molecular Function GO:0008168 methyltransferase activity
GO:0008170 N-methyltransferase activity
GO:0008276 protein methyltransferase activity
GO:0008757 S-adenosylmethionine-dependent methyltransferase activity
GO:0016278 lysine N-methyltransferase activity
GO:0016279 protein-lysine N-methyltransferase activity
GO:0016741 transferase activity, transferring one-carbon groups
GO:0018024 histone-lysine N-methyltransferase activity
GO:0042054 histone methyltransferase activity
GO:0042800 histone methyltransferase activity (H3-K4 specific)
Cellular Component GO:0034708 methyltransferase complex
GO:0035097 histone methyltransferase complex
> KEGG and Reactome Pathway
 
KEGG hsa00310 Lysine degradation
Reactome R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-3214841: PKMTs methylate histone lysines
Summary
SymbolKMT2B
Namelysine (K)-specific methyltransferase 2B
Aliases KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KMT2B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolKMT2B
Namelysine (K)-specific methyltransferase 2B
Aliases KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KMT2B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: 1.82; FDR: 0.000381 Sensitive to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolKMT2B
Namelysine (K)-specific methyltransferase 2B
Aliases KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KMT2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0560.784
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1950.895
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0450.968
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1720.61
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2580.926
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0680.985
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2860.37
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2980.839
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2780.865
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4280.506
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.880.299
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0840.21
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KMT2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.85.917.90.197
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.89.121.70.327
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.611.1-8.50.299
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.515.4-10.90.541
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKMT2B
Namelysine (K)-specific methyltransferase 2B
Aliases KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KMT2B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKMT2B
Namelysine (K)-specific methyltransferase 2B
Aliases KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KMT2B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KMT2B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKMT2B
Namelysine (K)-specific methyltransferase 2B
Aliases KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KMT2B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKMT2B
Namelysine (K)-specific methyltransferase 2B
Aliases KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KMT2B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKMT2B
Namelysine (K)-specific methyltransferase 2B
Aliases KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KMT2B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKMT2B
Namelysine (K)-specific methyltransferase 2B
Aliases KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location19q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KMT2B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.